[Comparative data from an experimental-clinical study of new antituberculosis drugs].
D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002224:Carbanilides / Q000494:pharmacology / Q000627:therapeutic use; D004977:Ethambutol / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010670:Phenylthiourea / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*; D013307:Streptomycin / Q000494:pharmacology / Q000627:therapeutic use*; D013440:Sulfides / Q000494:pharmacology / Q000627:therapeutic use; D013882:Thiosemicarbazones / Q000494:pharmacology / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D002224:Carbanilides; D010879:Piperazines; D013440:Sulfides; D013882:Thiosemicarbazones; D010670:Phenylthiourea; D004977:Ethambutol; D012293:Rifampin; D013307:Streptomycin
Sravnitel'nye dannye po éksperimental'no-klinicheskomu izucheniiu novoykh protivotuberkuleznykh preparatov.